Modulight Biotherapeutics Announces $12 Million Seed Funding for Novel Optogenetic Therapy to Treat Neurological Disorders
BOSTON, Nov. 12, 2025 /PRNewswire/ — Modulight Biotherapeutics, developer of novel optogenetic platform for the treatment of neurological disorders, announced today the closing of its Seed funding round raising $12.2 million. The Seed round was led by Jibe Ventures…